Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- John Gerecitano, MD, PhD
Sana Biotechnology, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal Adelaide Hospital
Adelaide, South Australia, Australia
- Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
- Linear Clinical Research Ltd
Nedlands, Western Australia, Australia
- City of Hope
Duarte, California, United States
- Stanford Cancer Institute
Palo Alto, California, United States
- Northside Hospital
Atlanta, Georgia, United States
- University of Kansas Medical Center
Fairway, Kansas, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 May 2023
- Primary completion
- 4 Nov 2025
- Completion
- 4 Nov 2038
- Last update posted
- 2 Oct 2025
- Registered enrollment
- 16
- Registry id
- NCT05878184
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.